NSE:EMCURE

2 stories mentioning NSE:EMCUREUpdated 44d ago

Every FINWIRES story that references NSE:EMCURE, newest first.

Emcure Pharmaceuticals Unit to Acquire Remaining Shares in Canada's Mantra Pharma for C$50 Million

Emcure Pharmaceuticals (NSE:EMCURE, BOM:544210) said its subsidiary Marcan Pharmaceuticals has agreed to acquire all outstanding Class E special shares of its step-down subsidiary, Mantra Pharma, for 50 million Canadian dollars.The transaction, subject to customary closing formalities under Canadian law, will leave Mantra as a wholly owned subsidiary of Marcan, according to a stock exchange filing on Friday.Quebec-based Mantra markets and distributes prescription drugs and natural health products.Shares of the company fell over 1% in recent trade.

BOM:544210NSE:EMCURE

Asia102d ago

Jefferies Adjusts Emcure Pharmaceuticals' Price Target to INR1,970 From INR1,780, Keeps at Buy

Emcure Pharmaceuticals (NSE:EMCURE, BOM:544210) has an average rating of buy and mean price target of 1,837.33 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

BOM:544210NSE:EMCURE

Track with the FINWIRES app suite

FolioX

Track NSE:EMCURE in your portfolio

WheelAI

Analyze NSE:EMCURE options with the wheel strategy

StockInsider

See market sentiment on NSE:EMCURE